Effect of alcohol consumption on nonalcoholic fatty liver disease

被引:21
作者
Weng, Gong [1 ]
Dunn, Winston [1 ]
机构
[1] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
关键词
Nonalcoholic fatty liver disease (NAFLD); nonalcoholic steatohepatitis (NASH); alcohol; DECREASED PREVALENCE; MORTALITY; METAANALYSIS; DRINKING; FIBROSIS; CANCER; NO;
D O I
10.21037/tgh.2019.09.02
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be 26.3% among the US population. A subset of this population exhibits an aggressive histological phenotype, nonalcoholic steatohepatitis (NASH) with >= stage 2 fibrosis, which may progress to cirrhosis. The definition of NAFLD excludes excessive alcohol intake, which is well known to cause alcoholic liver disease and will not be discussed here. Most NAFLD clinical trials use -14 drinks per week as the cutoff for excessive alcohol intake. Alcohol consumption below this threshold, which we define as moderate alcohol consumption, is common in the US. According to the 2012 Behavioral Risk Factor Surveillance System (BRFSS), 56% of the US adult population consume alcohol, but only 8.2% report drinking heavily and 18.3% report binge drinking. The American Association for the Study of Liver Diseases (AASLD) Practice Guidance of 2018 states that there are insufficient data to make a recommendation with regard to moderate alcohol consumption in patients with NAFLD, citing a lack of longitudinal studies that examine the impact of moderate alcohol consumption on disease progression and its extrahepatic harms versus benefits, specifically in individuals with established NAFLD. NAFLD prevalence studies have generally noted a negative correlation between modest alcohol consumption and NAFLD. However, prevalence studies have limited application to patients with established NAFLD who present to the clinic. There can also be many confounding factors, because modest alcohol consumption is also negatively associated with some NAFLD risk factors, and those risk factors may not be adequately adjusted for in analyses. The prevalence of NASH with significant fibrosis (>= F2) is more important because this is the group that is believed to have progressive disease. Thus, cohort studies of disease progression are more important from the patient's standpoint. Because these patients have already developed NAFLD or NASH, their interest lies in their odds of disease progression if they have moderate alcohol consumption compared to abstinence. It is also noteworthy that cardiovascular disease is the most important cause of death among patients with NAFLD. Moderate alcohol consumption has been associated with a reduction in overall mortality, but mostly in cardiovascular mortality. However, this protective effect has not been demonstrated specifically in patients with NAFLD.
引用
收藏
页数:5
相关论文
共 22 条
[1]  
Ajmera V, 2018, CLIN GASTROENTEROL H, V16, P341, DOI [10.1016/j.cgh.2017.11.040, 10.1016/j.cgh.2018.01.026]
[2]   Is Moderate Alcohol Use in Nonalcoholic Fatty Liver Disease Good or Bad? A Critical Review [J].
Ajmera, Veeral H. ;
Terrault, Norah A. ;
Harrison, Stephen A. .
HEPATOLOGY, 2017, 65 (06) :2090-2099
[3]   Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease [J].
Angulo, Paul ;
Kleiner, David E. ;
Dam-Larsen, Sanne ;
Adams, Leon A. ;
Bjornsson, Einar S. ;
Charatcharoenwitthaya, Phunchai ;
Mills, Peter R. ;
Keach, Jill C. ;
Lafferty, Heather D. ;
Stahler, Alisha ;
Haflidadottir, Svanhildur ;
Bendtsen, Flemming .
GASTROENTEROLOGY, 2015, 149 (02) :389-+
[4]   Light alcohol drinking and cancer: a meta-analysis [J].
Bagnardi, V. ;
Rota, M. ;
Botteri, E. ;
Tramacere, I. ;
Islami, F. ;
Fedirko, V. ;
Scotti, L. ;
Jenab, M. ;
Turati, F. ;
Pasquali, E. ;
Pelucchi, C. ;
Bellocco, R. ;
Negri, E. ;
Corrao, G. ;
Rehm, J. ;
Boffetta, P. ;
La Vecchia, C. .
ANNALS OF ONCOLOGY, 2013, 24 (02) :301-308
[5]  
Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003
[6]   The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J].
Chalasani, Naga ;
Younossi, Zobair ;
Lavine, Joel E. ;
Charlton, Michael ;
Cusi, Kenneth ;
Rinella, Mary ;
Harrison, Stephen A. ;
Brunt, Elizabeth M. ;
Sanyal, Arun J. .
HEPATOLOGY, 2018, 67 (01) :328-357
[7]   Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study [J].
Chang, Yoosoo ;
Cho, Yong Kyun ;
Kim, Yejin ;
Sung, Eunju ;
Ahn, Jiin ;
Jung, Hyun-Suk ;
Yun, Kyung Eun ;
Shin, Hocheol ;
Ryu, Seungho .
HEPATOLOGY, 2019, 69 (01) :64-75
[8]   Alcohol dosing and total mortality in men and women - An updated meta-analysis of 34 prospective studies [J].
Di Castelnuovo, Augusto ;
Costanzo, Simona ;
Bagnardi, Vincenzo ;
Donati, Maria Benedetta ;
Iacoviello, Licia ;
de Gaetano, Giovanni .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (22) :2437-2445
[9]   Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease [J].
Dunn, Winston ;
Xu, Ronghui ;
Schwimmer, Jeffrey B. .
HEPATOLOGY, 2008, 47 (06) :1947-1954
[10]   Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD) [J].
Dunn, Winston ;
Sanyal, Arun J. ;
Brunt, Elizabeth M. ;
Unalp-Arida, Aynur ;
Donohue, Michael ;
McCullough, Arthur J. ;
Schwimmer, Jeffrey B. .
JOURNAL OF HEPATOLOGY, 2012, 57 (02) :384-391